Lilly: New Expanded Indication for Verzenio
Lilly USA, LLC is pleased to announce a recent label change for Verzenio® (abemaciclib, 50 mg, 100 mg, 150 mg, and 200 mg tablets). On March 3, 2023, the US Food and Drug Administration (FDA) approved Verzenio + ET in an expanded indication for more patients with HR+, HER2–, node positive early breast cancer at high risk of recurrence.1 Patient selection is no longer restricted to those with a high Ki-67 score (≥20%). For Indication Statement and Important Safety Information, please see below. For more information, please read the Press Release here.